Latest Articles

Publication Date
A Lipid Metabolism and Lysosome-based Risk Signature for Prognosis and Immune Response Prediction in Uterine Corpus Endometrial Carcinoma - Frontiers

A Lipid Metabolism and Lysosome-based Risk Signature for Prognosis and Immune Response Prediction in Uterine Corpus Endometrial Carcinoma Frontiers

Published: Aug. 18, 2025, 5:24 p.m.
Menopause as a Critical Turning Point in Lipedema: The Estrogen Receptor Imbalance, Intracrine Estrogen, and Adipose Tissue Dysfunction Model.

Lipedema is a chronic, estrogen-sensitive adipose tissue disorder characterized by disproportionate subcutaneous fat accumulation, fibrosis, inflammation, and resistance to fat mobilization. Despite its high prevalence, lipedema remains poorly understood and …

Published: July 23, 2025, midnight
Diagnostic Potential of Serum Circulating miRNAs for Endometriosis in Patients with Chronic Pelvic Pain.

Background: Endometriosis is a chronic gynecological condition marked by ectopic endometrial-like tissue, leading to inflammation, pain, and infertility. Diagnosis is often delayed by up to 10 years. Identifying non-invasive biomarkers …

Published: July 21, 2025, midnight
Characterizing disease-associated microbiome signatures using matched... - researchgate.net

Characterizing disease-associated microbiome signatures using matched... researchgate.net

Published: July 17, 2025, 7:18 p.m.
Schoolboy's bank holiday petition gains over 20,000 signatures - Yahoo

Schoolboy's bank holiday petition gains over 20,000 signatures Yahoo

Published: June 30, 2025, 3 p.m.
Narrative review on expression of non-coding RNA in biofluids in conditions associated with couple infertility.

Couple infertility poses a health challenge, prompting research into its multifaceted aetiology. Non-coding RNA (ncRNA) expression has emerged as a candidate for elucidating couple infertility. This review explores the roles …

Published: March 24, 2025, midnight
ACR-368 OncoSignature Assay Receives FDA Breakthrough Device Designation for Endometrial Cancer - Pharmacy Times

ACR-368 OncoSignature Assay Receives FDA Breakthrough Device Designation for Endometrial Cancer Pharmacy Times

Published: Feb. 10, 2025, 2:34 p.m.
FDA Grants Breakthrough Device Designation to ACR-368 OncoSignature Assay for Endometrial Cancer - OncLive

FDA Grants Breakthrough Device Designation to ACR-368 OncoSignature Assay for Endometrial Cancer OncLive

Published: Feb. 5, 2025, 5:17 p.m.
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer - The Manila Times

Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer The Manila Times

Published: Feb. 5, 2025, 1:07 p.m.
The NLRP3 activation-related signature predicts the diagnosis and indicates immune characteristics in endometriosis.

Endometriosis (EMS) is a prevalent gynecological disease that leads to chronic pelvic pain and infertility in women of reproductive age. However, the underlying pathogenic genes and effective treatment for EMS …

Published: Jan. 31, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!